AMGN vs NBIX
Amgen Inc. and Neurocrine Biosciences, Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AMGN | NBIX |
|---|---|---|
| Revenue | $36.8B | $2.9B |
| Net income | $7.7B | $478.6M |
| Gross margin | 67.2% | 98.2% |
| Net margin | 21.0% | 16.7% |
| Return on equity | 106.1% | 16.4% |
| Diluted EPS | $14.23 | $4.67 |
| Dividend / share | $9.66 | — |
| Payout ratio | 66.5% | — |
| Free cash flow | $8.1B | $748.7M |
| Equity | $8.7B | $3.3B |
| Net debt / equity | 5.25× | — |
| Current ratio | 1.14× | 3.39× |
| Revenue CAGR 5y | 7.6% | 22.3% |
| Profit CAGR 5y | 1.2% | 3.3% |
AMGN bills 12.8× the revenue of NBIX, and keeps more of each dollar of revenue as profit (21.0% against 16.7%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Advertisement
AdSense · Leaderboard 728×90 · responsive
Revenue by year
10 years side by side
| Fiscal year | AMGN | NBIX |
|---|---|---|
| FY2025 | $36.8B | $2.9B |
| FY2024 | $33.4B | $2.4B |
| FY2023 | $28.2B | $1.9B |
| FY2022 | $26.3B | $1.5B |
| FY2021 | $26.0B | $1.1B |
| FY2020 | $25.4B | $1.0B |
| FY2019 | $23.4B | $788.1M |
| FY2018 | $23.7B | $451.2M |
| FY2017 | $22.8B | $161.6M |
| FY2016 | $23.0B | $15.0M |
Net income by year
Bottom line
| Fiscal year | AMGN | NBIX |
|---|---|---|
| FY2025 | $7.7B | $478.6M |
| FY2024 | $4.1B | $341.3M |
| FY2023 | $6.7B | $249.7M |
| FY2022 | $6.6B | $154.5M |
| FY2021 | $5.9B | $89.6M |
| FY2020 | $7.3B | $407.3M |
| FY2019 | $7.8B | $37.0M |
| FY2018 | $8.4B | $21.1M |
| FY2017 | $2.0B | $-142.5M |
| FY2016 | $7.7B | $-141.1M |
Advertisement
AdSense · Rectangle 336×280
More in this industry